Jennifer J D Morrissette

List of Publications by Year
in descending order

60	4,153	304743 22	144013 57
papers	citations	h-index	g-index

61	61	61	8344
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Science Translational Medicine, 2017, 9, .	12.4	1,116
2	Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature, 2018, 558, 307-312.	27.8	574
3	Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Nonâ€“Small Cell Lung Cancer. JAMA Oncology, 2019, 5, 173.	7.1	334
4	Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia. Cell, 2018, 173, 1439-1453.e19.	28.9	323
5	Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia. Cancer Discovery, 2019, 9, 1050-1063.	9.4	288
6	BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers. Nature Communications, 2017, 8, 319.	12.8	212
7	Epidermal Growth Factor Receptor Extracellular Domain Mutations in Glioblastoma Present Opportunities for Clinical Imaging and Therapeutic Development. Cancer Cell, 2018, 34, 163-177.e7.	16.8	145
8	Understanding the limitations of next generation sequencing informatics, an approach to clinical pipeline validation using artificial data sets. Cancer Genetics, 2013, 206, 441-448.	0.4	99
9	In vivoevaluation of EGFRvIII mutation in primary glioblastoma patients via complex multiparametric MRI signature. Neuro-Oncology, 2018, 20, 1068-1079.	1.2	90
10	Somatic HLA mutations expose the role of class Iâ€“mediated autoimmunity in aplastic anemia and its clonal complications. Blood Advances, 2017, 1, 1900-1910.	5.2	69
11	Using â€œresidualâ€•FNA rinse and body fluid specimens for nextâ€generation sequencing: An institutional experience. Cancer Cytopathology, 2016, 124, 324-329.	2.4	68
12	Clinical Utility of Plasma Cell-Free DNA in Adult Patients with Newly Diagnosed Glioblastoma: A Pilot Prospective Study. Clinical Cancer Research, 2020, 26, 397-407.	7.0	63
13	Genomic Signatures Predict the Immunogenicity of BRCA-Deficient Breast Cancer. Clinical Cancer Research, 2019, 25, 4363-4374.	7.0	60
14	Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia. Blood Advances, 2019, 3, 1581-1585.	5.2	57
15	Dramatic response to dabrafenib and trametinib combination in a BRAF V600E-mutated cholangiocarcinoma: implementation of a molecular tumour board and next-generation sequencing for personalized medicine. Ecancermedicalscience, 2014, 8, 479.	1.1	44
16	EGFRvIII upregulates DNA mismatch repair resulting in increased temozolomide sensitivity of MGMT promoter methylated glioblastoma. Oncogene, 2020, 39, 3041-3055.	5.9	42
17	A KRAS wild type mutational status confers a survival advantage in pancreatic ductal adenocarcinoma. Journal of Gastrointestinal Oncology, 2018, 9, 1-10.	1.4	39
18	PTEN and TP53 Mutations in Oncocytic Follicular Carcinoma. Endocrine Pathology, 2015, 26, 365-369.	9.0	30

#	Article	IF	Citations
19	Clinical Utility of Next-Generation Sequencing for Oncogenic Mutations in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 1961-1967.	2.0	30
20	A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600â€“Mutant Solid Tumors. Clinical Cancer Research, 2018, 24, 22-32.	7.0	30
21	Multiparametric magnetic resonance imaging in the assessment of anti-EGFRvIII chimeric antigen receptor T cell therapy in patients with recurrent glioblastoma. British Journal of Cancer, 2019, 120, 54-56.	6.4	27
22	Feasibility of monitoring advanced melanoma patients using cellâ€free <scp>DNA</scp> from plasma. Pigment Cell and Melanoma Research, 2018, 31, 73-81.	3.3	25
23	JAK2 V617Fâ€positive acute myeloid leukaemia (AML): a comparison between de novo AML and secondary AML transformed from an underlying myeloproliferative neoplasm. A study from the Bone Marrow Pathology Group. British Journal of Haematology, 2018, 182, 78-85.	2.5	22
24	NPM1 mutation is associated with leukemia cutis in acute myeloid leukemia with monocytic features. Haematologica, 2015, 100, e412-e414.	3.5	21
25	Comparative clinical utility of tumor genomic testing and cell-free DNA in metastatic breast cancer. Breast Cancer Research and Treatment, 2017, 164, 627-638.	2.5	21
26	Molecular Neuropathology in Practice: Clinical Profiling and Integrative Analysis of Molecular Alterations in Glioblastoma. Academic Pathology, 2019, 6, 2374289519848353.	1.1	21
27	KDR Mutation as a Novel Predictive Biomarker of Exceptional Response to Regorafenib in Metastatic Colorectal Cancer. Cureus, 2016, 8, e478.	0.5	20
28	Detection of Molecular Alterations in Medullary Thyroid Carcinoma Using Next-Generation Sequencing: an Institutional Experience. Endocrine Pathology, 2016, 27, 359-362.	9.0	20
29	Identification and Confirmation of Potentially Actionable Germline Mutations in Tumor-Only Genomic Sequencing. JCO Precision Oncology, 2019, 3, 1-11.	3.0	20
30	Validation of a Next-Generation Sequencing Assay Targeting RNA for the Multiplexed Detection of Fusion Transcripts and Oncogenic Isoforms. Archives of Pathology and Laboratory Medicine, 2020, 144, 90-98.	2.5	18
31	Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors. Clinical Cancer Research, 2015, 21, 5215-5221.	7.0	17
32	STK11 Mutation Identified in Thyroid Carcinoma. Endocrine Pathology, 2016, 27, 65-69.	9.0	17
33	Germline duplication of ATG2B and GSKIP genes is not required for the familial myeloid malignancy syndrome associated with the duplication of chromosome 14q32. Leukemia, 2018, 32, 2720-2723.	7.2	17
34	Germline POT1 variants can predispose to myeloid and lymphoid neoplasms. Leukemia, 2022, 36, 283-287.	7.2	17
35	What you are missing could matter: a rare, complex BRAF mutation affecting codons 599, 600, and 601 uncovered by next generation sequencing. Cancer Genetics, 2014, 207, 272-275.	0.4	16
36	Acute Myeloid Leukemia: Conventional Cytogenetics, FISH, and Moleculocentric Methodologies. Clinics in Laboratory Medicine, 2011, 31, 659-686.	1.4	14

#	Article	IF	Citations
37	A Modified Integrated Genetic Model for Risk Prediction in Younger Patients with Acute Myeloid Leukemia. PLoS ONE, 2016, 11, e0153016.	2.5	10
38	Rare Complex Mutational Profile in an ALK Inhibitor-resistant Non-small Cell Lung Cancer. Anticancer Research, 2015, 35, 3007-12.	1.1	10
39	Building a Robust Tumor Profiling Program: Synergy between Next-Generation Sequencing and Targeted Single-Gene Testing. PLoS ONE, 2016, 11, e0152851.	2.5	9
40	BRAF kinase domain mutations in de novo acute myeloid leukemia with monocytic differentiation. Leukemia and Lymphoma, 2017, 58, 743-745.	1.3	9
41	Transmission of an expanding donor-derived del(20q) clone through allogeneic hematopoietic stem cell transplantation without the development of a hematologic neoplasm. Cancer Genetics, 2015, 208, 625-629.	0.4	8
42	Classes of ITD Predict Outcomes in AML Patients Treated with FLT3 Inhibitors. Clinical Cancer Research, 2019, 25, 573-583.	7.0	8
43	Marginal zone lymphoma-derived interfollicular diffuse large B-cell lymphoma harboring 20q12 chromosomal deletion and missense mutation of BIRC3 gene: a case report. Diagnostic Pathology, 2016, 11, 137.	2.0	7
44	Negative prognostic impact of epidermal growth factor receptor copy number gain in young adults with isocitrate dehydrogenase wild-type glioblastoma. Journal of Neuro-Oncology, 2019, 145, 321-328.	2.9	7
45	Most Myeloid Neoplasms With Deletion of Chromosome 16q Are Distinct From Acute Myeloid Leukemia With Inv(16)(p13.1q22). American Journal of Clinical Pathology, 2017, 147, 411-419.	0.7	6
46	ROS1 Rearrangement in a Case of Classic Biphasic Pulmonary Blastoma. International Journal of Surgical Pathology, 2018, 26, 360-363.	0.8	6
47	Validation of a next-generation sequencing oncology panel optimized for low input DNA. Cancer Genetics, 2018, 228-229, 55-63.	0.4	6
48	NTRK point mutations and their functional consequences. Cancer Genetics, 2022, 262-263, 5-15.	0.4	6
49	Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors. Journal of Visualized Experiments, 2016, , .	0.3	5
50	Myelofibrosis patients can develop extramedullary complications including renal amyloidosis and sclerosing hematopoietic tumor while otherwise meeting traditional measures of ruxolitinib response. Leukemia and Lymphoma, 2019, 60, 852-855.	1.3	5
51	Interim PET/CT Result Is Not Predictive of Survival in Patients With MYC-rearranged Nonâ€“Burkitt Aggressive B-cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 673-678.	0.4	4
52	Rapid fluorescence in situ hybridisation optimises induction therapy for acute myeloid leukaemia. British Journal of Haematology, 2020, 191, 935-938.	2.5	3
53	Interpretative differences of combined cytogenetic and molecular profiling highlights differences between MRC and ELN classifications of AML. Cancer Genetics, 2021, 256-257, 68-76.	0.4	2
54	Reply. American Journal of Obstetrics and Gynecology, 2014, 211, 81.	1.3	1

#	Article	IF	Citations
55	FBXW7 mutations in acute myeloid leukemia. Leukemia and Lymphoma, 2019, 60, 1601-1602.	1.3	1
56	Mutational Analysis Reinforces the Diagnosis of Nodal Marginal Zone Lymphoma With Robust PD1-positive T-Cell Hyperplasia. American Journal of Surgical Pathology, 2021, 45, 143-145.	3.7	1
57	Development of an Integrated Database and Dashboard for Bone Marrow Specimen Triage. American Journal of Clinical Pathology, 2013, 140, A067-A067.	0.7	0
58	PATH-40. TARGETED NEXT GENERATION SEQUENCING (NGS) OF YOUNG ADULTS WITH ISOCITRATE-DEHYDROGENASE WILD-TYPE GLIOBLASTOMA (IDH-WT GBM) REVEALS NEGATIVE PROGNOSTIC IMPACT OF EPIDERMAL GROWTH FACTOR RECEPTOR AMPLIFICATION (EGFRAMP). Neuro-Oncology, 2018, 20, vi167-vi167.	1.2	0
59	Longitudinal targeted nextâ€generation sequencing in a patient with acute myeloid leukaemia. British Journal of Haematology, 2019, 186, 801-801.	2.5	0
60	ASXL1 Mutations in AML: Molecular Biomarker for Secondary AML?. Blood, 2014, 124, 2343-2343.	1.4	0